People · Operator

Richard I Markham

Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals

1
Companies
1
Filings
$60.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
CoLucid Pharmaceuticals, Inc.PharmaceuticalsSeries B$60.0M$1.3B2009
Operator network

Richard I Markham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Jesse I. Treu · 5 companies · 1 sharedJesse I. TreuArthur M. Pappas · 3 companies · 1 sharedArthur M. PappasRichard J. Markham · 2 companies · 1 sharedRichard J. MarkhamBernice C. Kuca · 1 companies · 1 sharedBernice C. KucaDaniel L. Boeglin · 1 companies · 1 sharedDaniel L. BoeglinJames F. White · 1 companies · 1 sharedJames F. WhiteLuc C. Marengere · 1 companies · 1 sharedLuc C. MarengereMartin C. Edwards · 1 companies · 1 sharedMartin C. EdwardsMathers P. Thomas · 1 companies · 1 sharedMathers P. ThomasNadia C. Rupniak · 1 companies · 1 sharedNadia C. RupniakNadia M. Rupniak · 1 companies · 1 sharedNadia M. RupniakThomas P. Mathers · 1 companies · 1 sharedThomas P. MathersTimothy C. Gupton · 1 companies · 1 sharedTimothy C. GuptonCoLucid Pharmaceuticals, Inc. · $60.0M raisedCoLucid Pharmaceutica…Richard I MarkhamRM
Richard I Markham Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Richard I Markham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Jesse I. Treu15
Arthur M. Pappas13
Richard J. Markham12
Thomas P. Mathers11
Nadia M. Rupniak11
James F. White11
Daniel L. Boeglin11
Bernice C. Kuca11
Martin C. Edwards11
Timothy C. Gupton11
Luc C. Marengere11
Nadia C. Rupniak11
Mathers P. Thomas11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.